Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Lonza upgraded to Overweight from Neutral at JPMorgan » 06:31
02/23/21
02/23
06:31
02/23/21
06:31
LZAGY

Lonza

$0.00 /

+ (+0.00%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser upgraded Lonza to Overweight from Neutral with a price target of CHF 680, up from CHF 600. Potential for capital deployment to boost the company's biologic fill finish capabilities over the next 12 months and one of the strongest topline growth stories in the space should drive share outperformance, Vosser tells investors in a research note.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

02/16/21 Deutsche Bank
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank
02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
01/08/21 Morgan Stanley
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley
Recommendations
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank » 12:16
02/16/21
02/16
12:16
02/16/21
12:16
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Lonza to CHF 680 from CHF 630 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
01/08/21 Morgan Stanley
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley
11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
Recommendations
Lonza price target raised to CHF 690 from CHF 410 at Berenberg » 14:18
02/10/21
02/10
14:18
02/10/21
14:18
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Berenberg analyst Xian…

Berenberg analyst Xian Deng raised the firm's price target on Lonza to CHF 690 from CHF 410 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
01/08/21 Morgan Stanley
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley
11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
Recommendations
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley » 12:11
02/02/21
02/02
12:11
02/02/21
12:11
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley raised the firm's price target on Lonza to CHF 645 from CHF 630 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

01/08/21 Morgan Stanley
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley
11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
Over a month ago
Hot Stocks
Capricor Therapeutics, Lonza enter collaboration for CAP-1002 » 09:26
01/12/21
01/12
09:26
01/12/21
09:26
CAPR

Capricor Therapeutics

$4.36 /

+0.03 (+0.69%)

, LZAGY

Lonza

$0.00 /

+ (+0.00%)

Capricor Therapeutics…

Capricor Therapeutics (CAPR) and Lonza (LZAGY) announced that the companies have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells technology for the treatment of Duchenne Muscular Dystrophy and complications arising from COVID-19. CAP-1002 completed the positive HOPE-2 phase 2 clinical trial and has been granted orphan drug designation by the FDA for the treatment of DMD. CAP-1002 also received FDA acceptance of its IND application for a phase 2 clinical trial of CAP-1002 in patients with COVID-19 in August 2020, as announced by Capricor. The agreement aims to expand Capricor's manufacturing capacity for potential late-stage clinical trials and commercialization. Operations will begin with a tech-transfer to Lonza's Houston center of excellence, where Lonza will perform process development activities for late-clinical and commercial-scale GMP manufacturing of CAP-1002.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

CAPR Capricor Therapeutics
$4.36 /

+0.03 (+0.69%)

CAPR Capricor Therapeutics
$4.36 /

+0.03 (+0.69%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
LZAGY Lonza
$0.00 /

+ (+0.00%)

01/08/21 Morgan Stanley
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley
11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
CAPR Capricor Therapeutics
$4.36 /

+0.03 (+0.69%)

CAPR Capricor Therapeutics
$4.36 /

+0.03 (+0.69%)

Recommendations
Lonza price target lowered to CHF 630 from CHF 640 at Morgan Stanley » 13:04
01/08/21
01/08
13:04
01/08/21
13:04
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley lowered the firm's price target on Lonza to CHF 630 from CHF 640 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
10/02/20 JPMorgan
Lonza downgraded to Neutral from Overweight at JPMorgan
Hot Stocks
Lonza, Arbor Biotechnologies enter gene editing technology licensing deal » 08:02
12/23/20
12/23
08:02
12/23/20
08:02
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Arbor Biotechnologies and…

Arbor Biotechnologies and Lonza announced a license agreement to provide Lonza with access to Arbor's next-generation CRISPR-based gene editing technology. Lonza will have the ability to utilize Arbor's proprietary technology in its bioproduction products and services. The financial details of this agreement were not disclosed.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

11/11/20 UBS
Lonza price target raised to CHF 610 from CHF 520 at UBS
11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
10/02/20 JPMorgan
Lonza downgraded to Neutral from Overweight at JPMorgan
Over a quarter ago
Recommendations
Lonza price target raised to CHF 610 from CHF 520 at UBS » 12:49
11/11/20
11/11
12:49
11/11/20
12:49
LZAGY

Lonza

$0.00 /

+ (+0.00%)

UBS analyst Patrick…

UBS analyst Patrick Rafaisz raised the firm's price target on Lonza to CHF 610 from CHF 520 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

11/09/20 KeyBanc
Lonza initiated with a Sector Weight at KeyBanc
10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
10/02/20 JPMorgan
Lonza downgraded to Neutral from Overweight at JPMorgan
09/14/20 Morgan Stanley
Lonza price target raised to CHF 640 from CHF 550 at Morgan Stanley
Initiation
Lonza initiated with a Sector Weight at KeyBanc » 17:19
11/09/20
11/09
17:19
11/09/20
17:19
LZAGY

Lonza

$0.00 /

+ (+0.00%)

KeyBanc analyst Paul…

KeyBanc analyst Paul Knight initiated coverage of Lonza with a Sector Weight rating and CHF 635 price target. The analyst said that the sales of the company's Specialty Chemicals unit in fiscal 2021 will reduce EBITDA and create difficult comparisons, but biologics can drive growth to 10% or higher.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

10/21/20 Societe Generale
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale
10/02/20 JPMorgan
Lonza downgraded to Neutral from Overweight at JPMorgan
09/14/20 Morgan Stanley
Lonza price target raised to CHF 640 from CHF 550 at Morgan Stanley
09/04/20 Societe Generale
Lonza price target raised to CHF 655 from CHF 600 at Societe Generale
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

Recommendations
Lonza price target raised to CHF 705 from CHF 655 at Societe Generale » 11:14
10/21/20
10/21
11:14
10/21/20
11:14
LZAGY

Lonza

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Justin Smith raised the firm's price target on Lonza to CHF 705 from CHF 655 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
LZAGY Lonza
$0.00 /

+ (+0.00%)

10/02/20 JPMorgan
Lonza downgraded to Neutral from Overweight at JPMorgan
09/14/20 Morgan Stanley
Lonza price target raised to CHF 640 from CHF 550 at Morgan Stanley
09/04/20 Societe Generale
Lonza price target raised to CHF 655 from CHF 600 at Societe Generale
08/26/20 Morgan Stanley
Lonza still well placed for outperformance, says Morgan Stanley
LZAGY Lonza
$0.00 /

+ (+0.00%)

LZAGY Lonza
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.